
Ariadna Recasens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2664815/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pathogenic Lysosomal Depletion in Parkinson's Disease. Journal of Neuroscience, 2010, 30, 12535-12544.	3.6	681
2	Lewy body extracts from Parkinson disease brains trigger αâ€synuclein pathology and neurodegeneration in mice and monkeys. Annals of Neurology, 2014, 75, 351-362.	5.3	521
3	Targeting Cancer Cell Dormancy. Trends in Pharmacological Sciences, 2019, 40, 128-141.	8.7	224
4	Alpha-synuclein spreading in Parkinsonââ,¬â"¢s disease. Frontiers in Neuroanatomy, 2014, 8, 159.	1.7	148
5	Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease. Molecular Therapy, 2018, 26, 550-567.	8.2	97
6	Optic atrophy 1 mediates mitochondria remodeling and dopaminergic neurodegeneration linked to complex I deficiency. Cell Death and Differentiation, 2013, 20, 77-85.	11.2	78
7	BAX channel activity mediates lysosomal disruption linked to Parkinson disease. Autophagy, 2014, 10, 889-900.	9.1	74
8	In vivo models of alpha-synuclein transmission and propagation. Cell and Tissue Research, 2018, 373, 183-193.	2.9	51
9	Role of microRNAs in the Regulation of $\hat{I}\pm$ -Synuclein Expression: A Systematic Review. Frontiers in Molecular Neuroscience, 2016, 9, 128.	2.9	38
10	Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates. Science Advances, 2020, 6, eaaz9165.	10.3	34
11	Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells. Cell Death Discovery, 2021, 7, 81.	4.7	31
12	Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients. Acta Neuropathologica Communications, 2018, 6, 8.	5.2	19
13	Lower Tubulin Expression in Glioblastoma Stem Cells Attenuates Efficacy of Microtubule-Targeting Agents. ACS Pharmacology and Translational Science, 2019, 2, 402-413.	4.9	14
14	DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells. International Journal of Molecular Sciences, 2021, 22, 4011.	4.1	12
15	MK2 Inhibition Induces p53-Dependent Senescence in Glioblastoma Cells. Cancers, 2020, 12, 654.	3.7	5
16	MerTK activity is not necessary for the proliferation of glioblastoma stem cells. Biochemical Pharmacology, 2021, 186, 114437.	4.4	2
17	Abstract A064: MK2 inhibition stabilizes wild-type and mutated p53 in glioblastoma cells and leads to different cellular responses. , 2019, , .		0